Adverse Events of Special Interest in Patients with Advanced Basal Cell Carcinoma Receiving Sonidegib: Long-Term 42-Month Results from the BOLT Study

Main Article Content

Alexander Guminski
Nicholas Squittieri
John T Lear

Keywords

Basal Cell carcinoma, Sonidegib, adverse effects

Abstract

Abstract not available.

References

1. Migden MR, et al. Lancet Oncol. 2015;16(6):716–28.

2. Odomzo (sonidegib) [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2017.

3. Australian Government Department of Health, ARTG 292262.

4. European Medicines Agency. Summary of Product Characteristics, WC500188762.

5. Swissmedic, Authorization Number 65065, 2015.

6. Migden MR, et al. J Clin Oncol. 2018; 36: Suppl abstr 9551.

7. Lear JT, et al. J Eur Acad Dermatol Venereol. 2018; 32 (3): 372–81.

8. Dummer R, et al. J Am Acad Dermatol. 2016; 75 (1): 113–25 e5.

9. Dummer R, et al. Br J Dermatol. 2019; 10.1111/bjd.18552.

10. Eisenhauer EA, et al. Eur J Cancer. 2009; 45 (2): 228–47.

11. World Health Organization. http://whqlibdoc.who.int/offset/WHO_OFFSET_48.pdf.

12. National Cancer Institute. Common Terminology Criteria for Adverse Events v4.03.

Article Sidebar

Poster PDF
Published
Sep 2, 2020
DOI https://doi.org/10.25251/skin.4.supp.66

Article Details

How to Cite
Guminski, A., Squittieri, N., & Lear, J. T. (2020). Adverse Events of Special Interest in Patients with Advanced Basal Cell Carcinoma Receiving Sonidegib: Long-Term 42-Month Results from the BOLT Study. SKIN The Journal of Cutaneous Medicine, 4(5), s67. https://doi.org/10.25251/skin.4.supp.66
Issue
Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Section
Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

<< < 1 2 3 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 > >>